This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Coeptis Therapeutics 過去の業績
過去 基準チェック /06
主要情報
-60.7%
収益成長率
-46.1%
EPS成長率
Pharmaceuticals 業界の成長 | 6.0% |
収益成長率 | -100.0% |
株主資本利益率 | -1,832.5% |
ネット・マージン | n/a |
前回の決算情報 | 30 Jun 2022 |
最近の業績更新
更新なし
Recent updates
収支内訳
収支内訳
Coeptis Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 22 | 0 | -38 | 35 | 0 |
31 Mar 22 | 0 | -31 | 28 | 0 |
31 Dec 21 | 0 | -13 | 14 | 0 |
30 Sep 21 | 0 | -15 | 14 | 0 |
30 Jun 21 | 0 | -11 | 9 | 0 |
31 Mar 21 | 0 | -9 | 7 | 0 |
31 Dec 20 | 0 | -9 | 6 | 0 |
31 Dec 19 | 0 | -2 | 3 | 1 |
31 Dec 18 | 0 | -2 | 0 | 2 |
質の高い収益: COEP is currently unprofitable.
利益率の向上: COEP is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: COEP is unprofitable, and losses have increased over the past 5 years at a rate of 60.7% per year.
成長の加速: Unable to compare COEP's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: COEP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.8%).
株主資本利益率
高いROE: COEP has a negative Return on Equity (-1832.5%), as it is currently unprofitable.